Stocks · News reference
102 patients enrolled across 14 European centers to assess safety and clinical performance of 35 mm and 40 mm Freesolve™ Resorbable Magnesium Scaffolds in long coronary lesionsTeleflex Incorporated (NYSE:TFX), a leading
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
The U.S. Food and Drug Administration has granted Breakthrough Device Designation to Teleflex's Freesolve™ Resorbable Magnesium Scaffold for use in percutaneous coronary intervention.
Teleflex Incorporated has scheduled its third quarter 2026 financial results conference call for November 5, 2026.
Truist Securities analyst Richard Newitter maintains Teleflex (NYSE:TFX) with a Hold and lowers the price target from $150 to $142.